MTIF has partnered with Normax to offer access to the BioXp system by Telesis Bio and to innovate in RNA technology.
MTIF are delighted to announce their new collaboration with Normax Biomed Limited to offer access to the BioXP 3250 system from Telesis Bio at their Research Facility to accelerate the development and discovery of new mRNA vaccines and gene therapies. On 31st January, MTIF partnered with Medilink Midlands to hold an event showcasing the BioXp, including a hands-on demo of the equipment and comprehensive presentation detailing the potential of the machine from its developers, Telesis Bio. We were also pleased to be joined by Peter Jensen, CEO of Normax Biomed, who have partnered with MTIF to bring the BioXp to their facility. The event brought together industry and academics to highlight the availability of the equipment within our region and to open the door to possible collaborative projects.
The BioXpTM is the world’s first commercially available end-to-end fully automated benchtop synthetic biology workstation created by Telesis Bio empowering scientists to accelerate discovery of new vaccines and biologics bypassing process limitations created by the turnaround time, cost, or complexity of alternative means of building or acquiring DNA and mRNA. The BioXp™ system provides over-night, automated synthesis of genes, clones, DNA libraries, and mRNA, enabling users to more tightly integrate design and build cycles, driving greater productivity and reducing time to answer.
Normax is on a mission to be a strategic partner in the global ecosystem for transformative research, development, and manufacture of safe and effective mRNA vaccines for global public health and pandemic preparedness and prevention. Through this new partnership, we can offer the BioXpTM system to accelerate the development and discovery of new mRNA and DNA vaccines and biologics from building, cloning, and amplifying gene fragments to constructing DNA variant libraries in less than a day.
MTIF provides Normax with access to prototypes, laboratory testing, support regulatory filings, human analysis, and clinical trials. Together, this collaboration will continue to facilitate the translation of innovations from bench to bedside.
“This exciting collaboration with MTIF is paving a pathway towards our mission to manufacture safe and effective mRNA vaccines for the world, enabling us to bring product into mass production. In the event of another public health emergency, we are also committed to delivering future mRNA vaccines in 100 days, to help ensure that COVID-19 is the last pandemic we will endure with such a global impact.”
Peter A. Jensen, CEO and Chairman of Normax
“We’re delighted to have signed this exciting collaboration agreement with Normax Biomed Ltd., enabling us to offer access to the BioXPTM in our MTIF facilities. This new technology which builds on our genomic sequencing capability and creates a value proposition in the research, development and discovery of future medical therapies including vaccines, will be installed at our MTIF facility in Nottingham and will be accessible to researchers, innovators from all sectors who are eager to create solutions for diseases and further develop personalised small-scale therapies.”
Dr Robert Reisel, Managing Director of the Medical Technologies Innovation Facility at Nottingham Trent University
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy.
Learn more about all the benefits from the new BioXP 3250 system here.